Kira Sheinerman discloses 51.56% Niki BioSolutions (NIKI) stake

Rhea-AI Filing Summary

Niki BioSolutions, Inc. director Kira S. Sheinerman reports beneficial ownership of 1,515,293 shares of Niki common stock, representing approximately 51.56% of the 2,938,625 shares outstanding as of the merger closing.

These shares were issued as non-cash merger consideration in exchange for DiamiR Biosciences Corp. stock under a July 14, 2025 merger agreement, which closed on July 20, 2026 when Aptorum Group Limited domesticated to Delaware and was renamed Niki BioSolutions, Inc. Under a Stockholders Agreement, Sheinerman may designate two board nominees while owning at least 36% of the common stock, and one nominee while owning at least 25%. While she holds at least 25%, certain significant corporate actions require her prior written consent, and transfers of covered shares are generally restricted for six months after the agreement’s effective date. Niki common stock trades on the Nasdaq Capital Market under the ticker symbol \"NIKI\".

Key Figures

Beneficial Ownership: 1,515,293 shares Ownership Percentage: 51.56 % Shares Outstanding: 2,938,625 shares +5 more

8 metrics

Beneficial Ownership 1,515,293 shares Shares of Niki common stock beneficially owned by Kira S. Sheinerman as of the merger closing

Ownership Percentage 51.56 % Percent of outstanding Niki common stock represented by 1,515,293 shares

Shares Outstanding 2,938,625 shares Niki common stock issued and outstanding as of the merger closing date

Sole Voting Power 1,515,016 shares Shares over which the reporting person has sole voting and dispositive power

Shared Voting Power 277 shares Shares in a joint Morgan Stanley account with shared voting and dispositive power

Board Nomination Threshold (two designees) 36 % Ownership level at which the reporting person may designate two director nominees

Board Nomination Threshold (one designee) 25 % Ownership level at which the reporting person may designate one director nominee and retain consent rights

Transfer Restriction Period 6 months General restriction on transfers of shares subject to the Stockholders Agreement after its effective date

Key Terms

Schedule 13D, beneficially owns, Stockholders Agreement, non-cash merger consideration, +1 more

5 terms

Schedule 13D regulatory

"If the filing person has previously filed a statement on Schedule 13G to report"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

beneficially owns financial

"the Reporting Person beneficially owns 1,515,293 shares of Niki Common Stock"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

Stockholders Agreement regulatory

"the Reporting Person entered into a Stockholders Agreement with the Issuer"

non-cash merger consideration financial

"Such shares were issued to the Reporting Person solely as non-cash merger consideration"

domestication regulatory

"Aptorum effected the domestication and became a Delaware corporation"

Domestication is the legal process by which a company changes its official ‘legal home’ from one place to another without creating a new business entity, similar to moving a household’s registration from one city to another while keeping the same people and possessions. It matters to investors because it can alter which laws, tax rules, reporting standards and shareholder rights apply, potentially affecting costs, governance and the value or liquidity of the company’s shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/24/2026 - 04:31 PM Accepted by SEC EDGAR 07/24/2026 - 04:31 PM Learn about SEC filing dates

FAQ

What percentage of Niki BioSolutions (APM) does Kira S. Sheinerman own?

Kira S. Sheinerman beneficially owns 51.56% of Niki BioSolutions common stock, or 1,515,293 shares, based on 2,938,625 shares outstanding as of the merger closing. This majority position is paired with board nomination and consent rights under a Stockholders Agreement.

How many Niki BioSolutions (APM) shares does Kira S. Sheinerman hold directly and jointly?

She holds 1,515,016 Niki shares directly with sole voting and dispositive power and 277 shares in a joint Morgan Stanley account with Felix Sheinerman. Voting and dispositive power over those 277 shares is shared between the joint account holders.

How did Kira S. Sheinerman acquire her Niki BioSolutions (APM) stake?

All reported Niki shares were received as non-cash merger consideration for DiamiR Biosciences Corp. common stock under a July 14, 2025 Agreement and Plan of Merger. No cash or other funds were used by her to acquire these Niki shares.

What governance rights does Kira S. Sheinerman have at Niki BioSolutions (APM)?

Under a Stockholders Agreement, she may designate two director nominees while owning at least 36% of Niki’s common stock and one nominee while owning at least 25%. While she holds at least 25%, certain significant corporate actions require her prior written consent.

When was the Niki BioSolutions (APM) merger completed and where is the stock listed?

The merger involving DiamiR Biosciences and Aptorum, which became Niki BioSolutions, Inc., was consummated on July 20, 2026. Niki common stock is listed on the Nasdaq Capital Market under the ticker symbol “NIKI”.

Are Kira S. Sheinerman’s Niki BioSolutions (APM) shares subject to transfer restrictions?

Yes. The Stockholders Agreement generally restricts transfers of covered Niki shares for six months following its effective date. These restrictions apply in addition to her ongoing ownership and governance rights described in the agreement.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Niki BioSolutions, Inc.

(Name of Issuer)

Common Stock, par value $0.0001

(Title of Class of Securities)

653942102

(CUSIP Number)

Kira S. Sheinerman
Niki BioSolutions, Inc., 116 Village Boulevard, Suite 200
Princeton, NJ, 08540
609-951-2222

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/20/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 653942102

1

Name of reporting person

Kira S. Sheinerman

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,515,016.00
8	Shared Voting Power 277.00
9	Sole Dispositive Power 1,515,016.00
10	Shared Dispositive Power 277.00

11

Aggregate amount beneficially owned by each reporting person

1,515,293.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

51.56 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

No funds or other consideration were used by the Reporting Person to acquire the shares of Common Stock reported herein. Such shares were issued to the Reporting Person solely as non-cash merger consideration in exchange for shares of common stock of DiamiR Biosciences Corp. previously held by the Reporting Person, pursuant to the Agreement and Plan of Merger, dated July 14, 2025, by and among Aptorum Group Limited, DiamiR Biosciences Corp. and the other parties thereto.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001
(b)	Name of Issuer: Niki BioSolutions, Inc.
(c)	Address of Issuer's Principal Executive Offices: 116 Village Boulevard, Suite 200, Princeton, NEW JERSEY , 08540.
Item 1 Comment: The Common Stock is listed on the Nasdaq Capital Market under the symbol NIKI.
Item 2.	Identity and Background
(a)	Kira S. Sheinerman
(b)	The principal business address of each Reporting Person is 116 Village Boulevard, Suite 200, Princeton, NJ 08540.
(c)	The Reporting Person is a Director of the Issuer.
(d)	No. During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	No. During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in such Reporting Person being subject to a judgment, decree or final order of the type described in Item 2(e).
(f)	The Reporting Person is a Citizen of the United States.
Item 3.	Source and Amount of Funds or Other Consideration
	No funds or other consideration were used by the Reporting Person to acquire the shares of Common Stock reported herein. Such shares were issued to the Reporting Person solely as non-cash merger consideration in exchange for shares of common stock of DiamiR Biosciences Corp. previously held by the Reporting Person, pursuant to the Agreement and Plan of Merger, dated July 14, 2025, by and among Aptorum Group Limited, DiamiR Biosciences Corp. and the other parties thereto.
Item 4.	Purpose of Transaction
	The information set forth in Items 3 and 6 is incorporated herein by reference. The shares of Niki Common Stock reported herein were acquired by the Reporting Person solely as merger consideration pursuant to the merger agreement, as described in Item 3 above. No funds or other consideration were expended by the Reporting Person in connection with the receipt of such shares. On July 20, 2026, the merger was consummated pursuant to the merger agreement. In connection with the merger, Aptorum effected the domestication and became a Delaware corporation, changing its name to Niki BioSolutions, Inc. The Niki Common Stock is listed on the Nasdaq Capital Market under the ticker symbol "NIKI" (CUSIP: 653942102). The Reporting Person is a party to that certain Stockholders Agreement, the final form of which is filed as Exhibit 4.5 hereto, which governs certain rights and obligations of the Reporting Person with respect to the Niki Common Stock. Reference is made to the Stockholders Agreement for a complete description of its terms, which are incorporated herein by reference.
Item 5.	Interest in Securities of the Issuer
(a)	As of the date hereof, the Reporting Person beneficially owns 1,515,293 shares of Niki Common Stock, representing approximately 51.56% of the outstanding shares of Niki Common Stock, in each case based on 2,938,625 shares of Niki Common Stock issued and outstanding as of the closing date of the merger. Of such shares, 1,515,016 shares are held directly by the Reporting Person and 277 shares are held in a joint brokerage account at Morgan Stanley in the names of Kira Sheinerman and Felix Sheinerman. The Reporting Person may be deemed to share voting and dispositive power over the 277 shares held in such joint account with Felix Sheinerman.
(b)	For each Reporting Person: sole voting power, 1,515,016; shared voting power, 277; sole dispositive power, 1,515,016; and shared dispositive power, 277.
(c)	Except for the transactions described in Items 3, 4 and 6 of this Schedule 13D, the Reporting Person has not effected any transaction in the Common Stock during the past 60 days.
(d)	Except with respect to 277 shares of Niki Common Stock held in a joint brokerage account at Morgan Stanley in the names of Kira Sheinerman and Felix Sheinerman, no person other than the Reporting Person is known to have the right to receive, or the power to direct the receipt of, dividends from, or proceeds from the sale of, the securities reported herein. Felix Sheinerman, as joint account holder, may be deemed to share such rights with respect to such 277 shares.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information set forth in Items 3, 4 and 5 is incorporated herein by reference. The following contracts, arrangements, understandings, or relationships exist among the persons named in Item 2 and between such persons and any other person with respect to any securities of the Company: In connection with the merger, the Reporting Person entered into a Stockholders Agreement with the Issuer. Under the Stockholders Agreement, the Reporting Person may designate two nominees for election to the Issuers board of directors while the Reporting Person collectively owns at least 36% of the Issuer's outstanding Common Stock, and one nominee while such ownership is at least 25%. Each such designation right permanently terminates if the applicable ownership threshold is no longer satisfied. The Reporting Person agreed to vote for such designees and, until the Issuer's 2027 annual meeting, in accordance with the recommendations of the Board's nominating and governance committee with respect to other director nominees. While the Reporting Person beneficially owns at least 25% of the Issuer's outstanding Common Stock, certain significant corporate actions require the prior written consent of the Reporting Person. The Stockholders Agreement also generally restricts transfers of shares subject thereto for six months following its effective date. The foregoing description is qualified in its entirety by reference to the Stockholders Agreement, filed as Exhibit 4.5 hereto and incorporated herein by reference. Except as described above, the Reporting Person is not a party to any contract, arrangement, understanding, or relationship with respect to any securities of the Company, including but not limited to any relating to the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, put or call options, security-based swaps or other derivative securities, guarantees of profits, division of profits or loss, or the giving or withholding of any proxy.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 4.5. Stockholders Agreement by and among Aptorum and stockholders of DiamiR (incorporated by reference to Exhibit 4.5 to the Issuer's Registration Statement on Form S-4 (File No. 333-290742)).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Kira S. Sheinerman

Signature:	/s/ Kira S. Sheinerman
Name/Title:	Kira S. Sheinerman, Director
Date:	07/24/2026